Washington, DC 10/16/13; San Diego, CA 10/21/13—Illumina had made two announcements about its future. On its third quarter conference call, the company said it is exiting the qPCR market. The company provides the Eco qPCR instrument and NuPCR assays. “This decision was due in part to our belief that sequencing delivers advantages over qPCR technology for gene expression applications,” stated President and CEO Jay Flatley on the call. The company will stop selling the products at year end. In a filing with the SEC, Illumina announced changes to its organizational structure and management team that will take effect on January 1, 2014. The president and CEO position currently held by Mr. Flatley will be split. The new president will focus on leading the business units and core functions responsible for developing and producing products. Mr. Flatley will focus on strategic vision and the management of commercial and corporate functions. The company also will create new business units, each of which will contain product marketing, market development, technology development and targeted informatics resources. In a letter to employees, Mr. Flatley wrote, “To ensure we can continue our rapid growth, we need to quickly catalyze, develop and penetrate markets that represent our largest opportunities. Our markets will require more focus on integrated solutions, ease of use and clinically actionable reports.” A new Life Sciences unit will focus on core platform technologies for markets such as complex disease, agrigenomics, microbiology and metagenomics. This unit will contain the Molecular Biology and PCR business, as well as a new Custom Products group. A new Reproductive and Genetic Health unit will combine the Verinata, Blue Genome and cytogenetics businesses. The three other new units will be Oncology, Enterprise Informatics, and New and Emerging Markets. In addition, the research and diagnostics commercial organizations and channels will be consolidated. Christian Henry, senior vice president and general manager of Genomic Solution, will become chief commercial officer. Product development, IVD development, operations, and quality and regulatory affairs will be centralized, reporting directly to the president.